Sign in

    Jonathan J. Mazelsky

    President and CEO at IDEXX Laboratories Inc
    Since November 4, 2019
    Age
    63 years
    Education
    Earned a Bachelor of Arts in Mathematics from the University of Rochester and an MBA from the University of Chicago.
    Tenure
    Joined IDEXX Laboratories as Executive Vice President in August 2012, served as Interim President and CEO from June 2019 to October 2019, and has been President and CEO since October 2019.

    Also at IDEXX Laboratories Inc

    AE
    Andrew Emerson
    EVP, CFO, and Treasurer (effective March 1, 2025)
    BPM
    Brian P. McKeon
    EVP, CFO, and Treasurer (until March 1, 2025)
    GJF
    George J. Fennell
    SVP, Chief Revenue Officer

    About

    Jonathan J. Mazelsky was born in 1961 and has built a multifaceted career within the healthcare, diagnostics, and technology sectors. Early in his career, he worked at Hewlett Packard, Agilent Technologies, and Philips Healthcare, where he gained deep expertise in finance, marketing, and strategic business planning.

    After proving his leadership capabilities in various high-level roles and overseeing key operational integrations, he joined IDEXX Laboratories in August 2012 as Executive Vice President. His experience in driving organizational transformation and innovation paved the way for his subsequent appointments within the company.

    Mazelsky's progression through roles at IDEXX, including his tenure as Interim President and CEO and later as the permanent President and CEO, reflects his strong commitment to operational excellence and strategic growth. His leadership has also extended beyond IDEXX, as evidenced by his role as a Director at Dentsply Sirona Inc. since May 2023.

    $IDXX Performance Under Jonathan J. Mazelsky

    Past Roles

    Organization Role Date Range Details
    IDEXX Laboratories, Inc. Interim President and CEO June 2019 - October 2019 Held as an interim leadership role prior to his full appointment.
    IDEXX Laboratories, Inc. Executive Vice President August 2012 - June 2019 Led the North American Companion Animal Group Commercial Organization and innovation portfolio including IDEXX VetLab® in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay, and Telemedicine.
    Philips Healthcare (Royal Philips) Senior Vice President and General Manager 2010 - 2012 Oversaw Computed Tomography, Nuclear Medicine, and Radiation Therapy Planning operations.
    Philips Healthcare (Royal Philips) Various Roles 2001 - 2010 Held roles of increasing responsibility.
    Agilent Technologies Executive in Charge 2000 - 2002 Led the integration of Agilent’s Healthcare Group into Philips.
    Agilent Technologies General Manager 1997 - 2000 Managed the Medical Consumables Business Unit.
    Hewlett Packard Various Roles 1988 - 1996 Worked in finance, marketing, and business planning.

    External Roles

    Organization Role Date Range
    Dentsply Sirona Inc. Director Since May 2023

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,000,000 AnnualFixed base salary for 2023.
    All Other Compensation$31,270 Annual/As incurredIncludes $16,500 in 401(k) matching contributions and additional tax preparation, financial planning fees, and insurance premiums.

    Performance Compensation

    Data from  FY 2023

    Annual Cash Bonus

    MetricValueDetails
    Target Bonus$1,250,000 125% of base salary.
    Actual Bonus$1,737,500 139% of the target bonus, reflecting performance exceeding set targets.
    Performance Weights60% Financial / 40% Non-Financial Bonus based on company financial performance against budget and achievement of non-financial/individual performance goals.
    Maximum Bonus Cap$2,500,000 200% of the target bonus.

    Evaluation and Conditions

    MetricValueDetails
    Evaluation PeriodFiscal Year 2023Bonus performance is evaluated over the fiscal year 2023.
    ConditionsPerformance Targets Met No bonus is paid if the minimum performance goals are not met. (Note: No detailed thresholds or target metrics disclosed.)

    No vesting schedule is applicable as the cash bonus is awarded based on annual performance.